Keeley Teton Advisors LLC Boosts Stake in Enovis Co. (NYSE:ENOV)

Keeley Teton Advisors LLC grew its position in shares of Enovis Co. (NYSE:ENOV) by 6.8% during the first quarter, according to its most recent filing with the SEC. The firm owned 6,936 shares of the company’s stock after acquiring an additional 441 shares during the period. Keeley Teton Advisors LLC’s holdings in Enovis were worth $433,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Fidelis Capital Partners LLC purchased a new stake in shares of Enovis in the 1st quarter worth approximately $34,000. Principal Securities Inc. purchased a new stake in shares of Enovis in the 4th quarter worth approximately $41,000. Benjamin F. Edwards & Company Inc. grew its stake in shares of Enovis by 97.2% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 846 shares of the company’s stock worth $47,000 after buying an additional 417 shares during the last quarter. GAMMA Investing LLC purchased a new stake in shares of Enovis in the 4th quarter worth approximately $53,000. Finally, Signaturefd LLC grew its stake in shares of Enovis by 197.4% in the 4th quarter. Signaturefd LLC now owns 2,257 shares of the company’s stock worth $126,000 after buying an additional 1,498 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Price Performance

Shares of NYSE:ENOV traded up $1.19 during midday trading on Friday, hitting $48.10. The company had a trading volume of 931,530 shares, compared to its average volume of 647,054. The company has a current ratio of 2.10, a quick ratio of 1.03 and a debt-to-equity ratio of 0.40. Enovis Co. has a 12-month low of $43.04 and a 12-month high of $65.53. The company has a fifty day moving average of $46.53 and a two-hundred day moving average of $54.34.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.50 EPS for the quarter, hitting the consensus estimate of $0.50. The firm had revenue of $516.00 million during the quarter, compared to analyst estimates of $505.62 million. Enovis had a positive return on equity of 3.98% and a negative net margin of 4.51%. Enovis’s revenue was up 27.0% on a year-over-year basis. During the same period in the prior year, the business posted $0.44 EPS. As a group, analysts anticipate that Enovis Co. will post 2.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ENOV has been the topic of several analyst reports. JPMorgan Chase & Co. initiated coverage on Enovis in a research report on Thursday, June 13th. They issued a “neutral” rating and a $53.00 price objective on the stock. Evercore ISI lowered their price objective on Enovis from $70.00 to $62.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 2nd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Enovis in a research report on Friday, May 3rd. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $71.44.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.